Held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners and joined BenevolentAI as CEO of BenevolentBio in 2016. Jackie has vast academic and business experience in the biomedical and pharmaceutical sectors. She directs the application of BenevolentAI’s technology for drug development and gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.
Serial entrepreneur, investor and healthcare and technology veteran with more than 20 years of business leadership experience. He is currently a director of BenevolentAI, a technology company he founded, which is developing and using Artificial Intelligence to change the way knowledge is created and applied in Life Sciences. He was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for central nervous system (CNS) disorders
CEO of BenevolentTech
Jerome is an expert in the commercialisation of AI. He co-founded Vivisimo, a tech firm specialising in text mining and enterprise search engines, which was acquired by IBM. At IBM he became chief scientist of big data, and created and led the development of the Watson Platform - the first comprehensive cloud platform for artificial intelligence.
Bart is a disruptive technology industry leader having held senior positions at some of the world’s most respected technology companies. Bart previously served on the boards of DeepMind, Summly and Onavo, acquired by Google, Yahoo and Facebook respectively. Bart is currently an Advisor to Horizons Ventures and holds Directorships with Viv Labs, Sentient Technologies, Cortica Ltd, Shine Security, Zoom.us, Hola, Modern Meadow and Impossible Foods Inc. among others.
VP Drug Discovery
Anne Phelan is Vice President of Drug Discovery at BenevolentBio. She has over 20 years experience in the pharmaceutical industry. She held a number of senior positions within Pfizer most recently as COO and Head of Pharmacology at Pfizer Neusentis in Cambridge UK. She has experience of drug development in a number of therapateutic areas including neuroscience, anti-virals and cardiovascular diseases. She has been responsible for the delivery of both clinical and preclinical portfolios within Pfizer.
VP Business Development
Ivan Griffin is Vice President of Business Development at BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, spin-out company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he completed a year’s post-doctoral research.
Chief Medical Officer
Dr Keohane trained as a Gastroenterologist in the UK NHS, and worked for the Medical Research Council.
He has held Project leadership and senior Management positions in Research and Development at Eli Lilly and Astrazeneca, and has been located in US, Japan, and Europe.
He joins from Glenmark Pharmaceuticals where he held the position of Chief Medical Officer.
Dr Keohane brings extensive experience in the medical assessment and worldwide development and launch of multiple novel oral, biologic, and inhaled medicines, across several Therapeutic areas including Immunology, Diabetes, Respiratory, and Neuroscience.
Chief Development Officer
Brent is Chief Development Officer of BenevolentAI. Previously, he founded TouchDx in 2009 developing the first portfolio of health specific phone apps – these focused on the diagnosis, monitoring, and compliance of patients with neurological and movement disorders.
Prior to TouchDx he founded E-Auction, the only company to successfully compete with eBay, in P2P auctions: being of similar size upon selling to Times Mirror. In parallel he founded Collectors Universe and after merging with leading firms in the collectibles industry completed a successful IPO in collectibles.
Head of Corporate Development
Senior corporate finance executive with over 15 years City based capital markets experience, Michael left the City in 2009 to join Ken Mulvany at Proximagen where he undertook the role of Head of Corporate Development, focusing on fund raising, corporate transactions, business development and ultimately the successful sale of the company in 2012.
Rosie has over 20 years experience as a creative leader in digital innovation and product development. She started her career as Creative Director of CHBi, one of the first web agencies anywhere in the world, acquired by Razorfish in 1998. She followed CHBi’s founders to Fjord, leading transformational multi-channel service design projects for clients including Skype, Greenpeace and Vodafone. More recently, Rosie has worked with start-ups, leading design and product on several consumer apps, engaging millions of users globally and occasionally hitting the top spot in the App Store for Top Grossing and Top Paid and Top Free.
VP Biomedical Informatics
John Overington is Vice President of Biomedical Informatics at BenevolentBio. John has over twenty-five years of experience in drug discovery and informatics, and has worked in large pharma, biotech, and academia, with a history of technical and strategic innovation.
While at Pfizer he led a multidisciplinary group combining rational drug design with structural biology. His time at Inpharmatica saw him lead the development of a series of computational and data platforms to improve drug discovery, including the medicinal chemistry database StARLite – also overseeing its transfer over to the EMBL-EBI in 2008.
VP CORPORATE AFFAIRS
James is VP of Corporate Affairs responsible for overseeing BenevolentAI’s marketing and communications activities. Before joining BenevolentAI, James held Board and senior management positions with a number of respected communications consultancies. He is a specialist in corporate affairs, investor relations, public affairs and marketing communications - advising technology companies of all sizes - from start-ups to global industry leaders, across multiple geographies.
Every day is an opportunity, if you are talented, ambitious and share our values, contact us.
If battling diseases is your thing, come and join the team to help deliver the next big drug discovery
Come join the team and help us develop the next major breakthrough in applied AI technology